Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study.

Revista do Instituto de Medicina Tropical de Sao Paulo - 1 Jan 2022

Shousha Hend Ibrahim, Abdelghafour Reem, Dabees Hosam, AbdelRazek Wael, Said Mohamed

Abstract excerpt

Despite the high sustained virologic response (SVR) rates of direct-acting antiviral (DAAs) therapy, a small number of patients does not eradicate the virus, and these patients represent a challenge. This study aims to compare the outcomes of three second-line regimens for DAAs-experienced patients with chronic hepatitis C (CHC). This prospective observational study was conducted at the Damanhur Viral Hepatitis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Ribavirin

Share to Sofosbuvir

Share to Treatment Failure

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 36074445
DOI: 10.1590/S1678-9946202264050
PMCID: PMC9448256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study.PMID 36074445Read ↗

Efficacy of Sofosbuvir-Velpatasvir-Ribavirin Regimen for Retreatment of Chronic Hepatitis C in Patients with Prior DAA Failure: A Retrospective Study from a National Treatment CenterSemantic proximity Read ↗

Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens.Semantic proximity Read ↗

Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies.Semantic proximity Read ↗

Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C.Semantic proximity Read ↗

Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.Semantic proximity Read ↗

Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort.Semantic proximity Read ↗

Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey.Semantic proximity Read ↗

Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.Semantic proximity Read ↗

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens.Semantic proximity Read ↗

Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir retreatment in hepatitis C patients with different genotypes with DAAs failure in East ChinaSemantic proximity Read ↗

Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.